exon 51 mutations in DMD

AVI BioPharma has begun phase 2 testing of its experimental exon-skipping drug eteplirsen (AVI-4658) in boys with Duchenne MD

posted on August 15, 2011 - 11:37am
Updated: View MDA's video about the launch of the eteplirsen trial on YouTube.

A 26-week study by AVI BioPharma finds that intravenous AVI4658 appears safe and beneficial to Duchenne MD patients with mutations in or around exon 51

posted on October 15, 2010 - 1:12pm
The experimental drug AVI4658, in development by AVI BioPharma to treat Duchenne muscular dystrophy (DMD) caused by specific genetic mutations, was well tolerated and resulted in increased production of the needed dystrophin protein. Measured aspects of cardiac, pulmonary and skeletal muscle function remained stable.